10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# PPP1R13L Antibody (N-Term)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP21503a

## Product Information

| | |
|---|---|
| **Application** | WB, IF, E |
| **Primary Accession** | Q8WUF5 |
| **Reactivity** | Human, Mouse |
| **Predicted** | Rat, Bovine |
| **Host** | Rabbit |
| **Clonality** | polyclonal |
| **Isotype** | Rabbit IgG |
| **Clone Names** | RB53806 |
| **Calculated MW** | 89091 |

## Additional Information

| | |
|---|---|
| **Gene ID** | 10848 |
| **Other Names** | RelA-associated inhibitor, Inhibitor of ASPP protein, Protein iASPP, NFkB-interacting protein 1, PPP1R13B-like protein, PPP1R13L, IASPP, NKIP1, PPP1R13BL, RAI |
| **Target/Specificity** | This PPP1R13L antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 134-166 amino acids from human PPP1R13L. |
| **Dilution** | WB~~1:2000 IF~~1:25 E~~Use at an assay dependent concentration. |
| **Format** | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| **Storage** | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| **Precautions** | PPP1R13L Antibody (N-Term) is for research use only and not for use in diagnostic or therapeutic procedures. |

## Protein Information

| | |
|---|---|
| **Name** | PPP1R13L |
| **Synonyms** | IASPP, NKIP1, PPP1R13BL, RAI |
| **Function** | Regulator that plays a central role in regulation of apoptosis and |

transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis (PubMed:12524540). Is involved in NF-kappa-B dependent negative regulation of inflammatory response (PubMed:28069640).

**Cellular Location** Cytoplasm. Nucleus Note=Predominantly cytoplasmic but also nuclear

**Tissue Location** Highly expressed in heart, placenta and prostate. Weakly expressed in brain, liver, skeletal muscle, testis and peripheral blood leukocyte.


## Background

Regulator that plays a central role in regulation of apoptosis and transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis.


## References


Slee E.A.,et al.Oncogene 23:9007-9016(2004).
Herron B.J.,et al.Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
Yang J.-P.,et al.J. Biol. Chem. 274:15662-15670(1999).
Takada N.,et al.J. Virol. 76:8019-8030(2002).
Bergamaschi D.,et al.Nat. Genet. 33:162-167(2003).


## Images



Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-2 OS (human bone osteosarcoma cell line) cells labeling PPP1R13L with AP21503a at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG (NK179883) secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on U-2 OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin (PD18466410) at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).




All lanes : Anti-PPP1R13L Antibody (N-Term) at 1:2000 dilution Lane 1: MCF-7 whole cell lysates Lane 2: Hela whole cell lysates Lane 3: NCI-H1299 whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 89 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.